Logo image of REVB

REVELATION BIOSCIENCES INC (REVB) Stock Fundamental Analysis

NASDAQ:REVB - Nasdaq - US76135L5075 - Common Stock

0.4129  +0.01 (+3.2%)

Premarket: 0.3955 -0.02 (-4.21%)

Fundamental Rating

1

REVB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of REVB is average, but there are quite some concerns on its profitability. REVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year REVB has reported negative net income.
REVB had a negative operating cash flow in the past year.
In the past 5 years REVB always reported negative net income.
In the past 5 years REVB always reported negative operating cash flow.
REVB Yearly Net Income VS EBIT VS OCF VS FCFREVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -230.20%, REVB is not doing good in the industry: 91.86% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -580.33%, REVB is doing worse than 81.42% of the companies in the same industry.
Industry RankSector Rank
ROA -230.2%
ROE -580.33%
ROIC N/A
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REVB Yearly ROA, ROE, ROICREVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for REVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REVB Yearly Profit, Operating, Gross MarginsREVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, REVB has more shares outstanding
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
REVB Yearly Shares OutstandingREVB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
REVB Yearly Total Debt VS Total AssetsREVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -11.27, we must say that REVB is in the distress zone and has some risk of bankruptcy.
REVB has a worse Altman-Z score (-11.27) than 77.17% of its industry peers.
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.27
ROIC/WACCN/A
WACCN/A
REVB Yearly LT Debt VS Equity VS FCFREVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

REVB has a Current Ratio of 1.64. This is a normal value and indicates that REVB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.64, REVB is not doing good in the industry: 81.42% of the companies in the same industry are doing better.
A Quick Ratio of 1.64 indicates that REVB should not have too much problems paying its short term obligations.
REVB has a Quick ratio of 1.64. This is amonst the worse of the industry: REVB underperforms 80.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.64
REVB Yearly Current Assets VS Current LiabilitesREVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

REVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -259.62%.
EPS 1Y (TTM)-259.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

REVB is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -56.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-113.8%
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%
EPS Next 5Y-56.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
REVB Yearly Revenue VS EstimatesREVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
REVB Yearly EPS VS EstimatesREVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -200 -400 -600 -800

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

REVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year REVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REVB Price Earnings VS Forward Price EarningsREVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REVB Per share dataREVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as REVB's earnings are expected to decrease with -26.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%

More info and screens

0

5. Dividend

5.1 Amount

REVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVELATION BIOSCIENCES INC

NASDAQ:REVB (1/21/2025, 8:23:41 PM)

Premarket: 0.3955 -0.02 (-4.21%)

0.4129

+0.01 (+3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)N/A N/A
Inst Owners1.35%
Inst Owner Change0%
Ins Owners0.08%
Ins Owner Change0%
Market Cap3.45M
Analysts82.86
Price Target13.01 (3050.88%)
Short Float %2.88%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.82%
Min EPS beat(2)-178.64%
Max EPS beat(2)71%
EPS beat(4)3
Avg EPS beat(4)-2.93%
Min EPS beat(4)-178.64%
Max EPS beat(4)71%
EPS beat(8)6
Avg EPS beat(8)63.92%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)55.19%
EPS NY rev (1m)0%
EPS NY rev (3m)39.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-16.76
EYN/A
EPS(NY)-2.17
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS0.32
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -230.2%
ROE -580.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.64
Altman-Z -11.27
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-259.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.33%
EPS Next Y-113.8%
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%
EPS Next 5Y-56.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.05%
OCF growth 3YN/A
OCF growth 5YN/A